DexCom Inc.

05/28/2026 | Press release | Distributed by Public on 05/28/2026 15:17

Proxy Results (Form 8-K)

ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
On May 27, 2026, DexCom, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). At the close of business on April 1, 2026, the record date for the Annual Meeting, there were 385,872,977 shares of Dexcom's common stock, $0.001 par value per share, outstanding and entitled to vote. 336,525,352 shares were present in person or represented by proxy at the Annual Meeting, which constituted a quorum for the transaction of business.
The matters described below were voted on at the Annual Meeting and the final number of votes cast for or against, as well as the number of abstentions and broker non-votes, with respect to each matter are as indicated.
Proposal 1: Election of Directors. Dexcom stockholders elected the following twelve nominees to the Company's board of directors, each to serve until Dexcom's 2027 annual meeting of stockholders or until their earlier death, resignation or removal, as follows:
Name Votes For Votes Against Abstentions Broker
Non-Votes
Steven Altman 299,051,663 15,262,716 102,979 22,107,994
Dr. Euan Ashley 309,712,364 4,597,357 107,637 22,107,994
Nicholas Augustinos 265,917,901 47,957,634 541,823 22,107,994
Richard Collins 301,710,498 12,602,265 104,594 22,107,994
Rimma Driscoll 313,600,504 723,603 93,251 22,107,994
Mark Foletta 308,685,713 5,641,368 90,277 22,107,994
Renée Galá 313,216,735 1,110,152 90,471 22,107,994
Bridgette Heller 297,000,591 17,328,487 88,280 22,107,994
Jacob Leach 312,218,781 2,104,043 94,534 22,107,994
Kyle Malady 313,438,268 885,232 93,858 22,107,994
Rick Osterloh 312,967,950 1,356,590 92,818 22,107,994
Kevin Sayer 307,497,531 6,831,418 88,409 22,107,994
Proposal 2: Ratification of Independent Registered Public Accounting Firm. Dexcom stockholders ratified the selection by the audit committee of the board of directors of Deloitte & Touche LLP as Dexcom's independent registered public accounting firm for the fiscal year ending December 31, 2026, as follows:
Votes For Votes Against Abstentions Broker
Non-Votes
336,046,596 373,544 105,212 -
Proposal 3: Advisory Vote to Approve Named Executive Officer Compensation. Dexcom stockholders approved, on a non-binding advisory basis, the compensation of Dexcom's named executive officers, as disclosed pursuant to Item 402 of Regulation S-K in the proxy statement for the Annual Meeting (which disclosure includes the Compensation Discussion and Analysis, the compensation tables and the narrative disclosures that accompany the compensation tables in such proxy statement), as follows:
Votes For Votes Against Abstentions Broker
Non-Votes
277,111,475 36,664,959 640,924 22,107,994
DexCom Inc. published this content on May 28, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 28, 2026 at 21:17 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]